These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10996622)

  • 1. Dendritic cell based tumor vaccines.
    Nouri-Shirazi M; Banchereau J; Fay J; Palucka K
    Immunol Lett; 2000 Sep; 74(1):5-10. PubMed ID: 10996622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
    Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
    J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third generation dendritic cell vaccines for tumor immunotherapy.
    Frankenberger B; Schendel DJ
    Eur J Cell Biol; 2012 Jan; 91(1):53-8. PubMed ID: 21439674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
    Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
    Wu Y; Wang L; Zhang Y
    Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.
    Nguyen-Pham TN; Yang DH; Nguyen TA; Lim MS; Hong CY; Kim MH; Lee HJ; Lee YK; Cho D; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Lee JJ
    Cell Mol Immunol; 2012 Jan; 9(1):45-53. PubMed ID: 21822297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
    Sun K; Wang L; Zhang Y
    Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic Cells and Cancer Immunity.
    Gardner A; Ruffell B
    Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in dendritic cell-based vaccine of cancer.
    Zhang X; Gordon JR; Xiang J
    Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dendritic cell-based therapeutic cancer vaccines].
    Rizzo M; Alaniz L; Mazzolini GD
    Medicina (B Aires); 2016; 76(5):307-314. PubMed ID: 27723619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.